Axel Baumgarten

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

Susan Swindells, Jaime Andrade‐Villanueva, Gary Richmond et al. · New England Journal of Medicine · 2020 · 523 citations · Full text

Brief Report

Sharon Walmsley, Axel Baumgarten, Juan Berenguer et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2015 · 215 citations · Full text

Noninferiority Study, Immunodeficiencies, Single Study +12

HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe

Patrick Ingiliz, Thomas Martin, Alison Rodger et al. · Journal of Hepatology · 2016 · 173 citations

Sexual Health, Viral Persistence, Spontaneous Clearance Rates +11

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

David A. Wohl, Yazdan Yazdanpanah, Axel Baumgarten et al. · The Lancet HIV · 2019 · 160 citations

Week 96, Treatment And Prevention, Antiviral Drug Development +9

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax et al. · The Lancet HIV · 2018 · 140 citations

Treatment And Prevention, Antiviral Drug Development, Clinical Trials +7